During this transformative phase to right size and focus the laboratory operations, ProPhase faced numerous one-time charges, including more than $2.4 million in startup costs. It also equipped Nebula ...

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re ...

ProPhase Labs, Inc. (PRPH) shares ended the last trading session 8.5% higher at $8.42. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Prophase Labs ((PRPH)) has held its Q2 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and ...

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...

ProPhase Labs (NASDAQ:PRPH) stock rose +12% Tuesday premarket as it named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered health ...

Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...

Access the complete ProPhase Labs Research Report, along with 1,400+ other detailed company analyses, exclusively on InvestingPro. In other recent news, ProPhase Labs Inc. has reported its ...

The latest price target for ProPhase Labs (NASDAQ:PRPH) was reported by HC Wainwright & Co. on February 21, 2024. The analyst firm set a price target for $11.00 expecting PRPH to rise to within 12 ...

GARDEN CITY, NY, Aug. 11, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a diversified medical science and technology company, today announces the ...